Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 19/20 | 0.42 |
| ▸ | GNA15 | P30679 | 1/20 | 0.40 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.40 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17385947 | 0.91 | FFAR1 (0.41) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17386274 | 0.87 | FFAR1 (0.40) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17385996 | 0.85 | FFAR1 (0.40) | FFAR1 | |
| SCHEMBL17399990 | 0.85 | MAPT (0.44) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17385818 | 0.85 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL17386062 | 0.85 | FFAR1 (0.44) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17386253 | 0.84 | ALDH1A1 (0.44) | ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL17418097 | 0.83 | FFAR1 (0.41) | FFAR1 | |
| SCHEMBL17385760 | 0.83 | FFAR1 (0.45) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17386246 | 0.82 | TSHR (0.39) | FFAR1ALDH1A1LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | FFAR1 22/4885GNA15 631/4885SLC10A1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.